NASDAQ:PODD Insulet (PODD) Stock Price, News & Analysis $237.06 -14.75 (-5.86%) Closing price 04:00 PM EasternExtended Trading$238.48 +1.41 (+0.60%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Insulet Stock (NASDAQ:PODD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Insulet alerts:Sign Up Key Stats Today's Range$230.05▼$249.6250-Day Range$237.06▼$288.2952-Week Range$160.19▼$289.46Volume1.60 million shsAverage Volume687,372 shsMarket Capitalization$16.65 billionP/E Ratio40.94Dividend YieldN/APrice Target$292.06Consensus RatingModerate Buy Company OverviewInsulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.Read More… Remove Ads Insulet Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScorePODD MarketRank™: Insulet scored higher than 95% of companies evaluated by MarketBeat, and ranked 44th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingInsulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 14 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageInsulet has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insulet's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth26.79% Earnings GrowthEarnings for Insulet are expected to grow by 26.79% in the coming year, from $3.92 to $4.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 40.94, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.50.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 40.94, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.90.Price to Earnings Growth RatioInsulet has a PEG Ratio of 3.62. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioInsulet has a P/B Ratio of 22.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Insulet's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.09% of the float of Insulet has been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently decreased by 11.48%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Sustainability and ESG4.9 / 5Environmental Score-1.20 Percentage of Shares Shorted3.09% of the float of Insulet has been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently decreased by 11.48%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News Sentiment0.87 News SentimentInsulet has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 27 news articles for Insulet this week, compared to 10 articles on an average week.Search InterestOnly 5 people have searched for PODD on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows3 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,722,512.00 in company stock.Percentage Held by InsidersOnly 0.47% of the stock of Insulet is held by insiders.Read more about Insulet's insider trading history. Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address PODD Stock News HeadlinesInsulet (NASDAQ:PODD) shareholders YoY returns are lagging the company's 15% five-year earnings growthMarch 10 at 7:01 PM | uk.finance.yahoo.comInsulet Corp (PODD) Stock Price Down 4.67% on Mar 10March 10 at 1:48 PM | gurufocus.comMarch 18th: Gold SHOCK? On March 18th, an event is taking place that could completely shock the market. Stocks could go ballistic… Businesses could get blindsided… The gold market could get rocked… And one man, millionaire trader Jeff Clark is pounding the table on one single stock before this event. Because this one single stock has shown his readers gains of 85% in 14 days, 120% in under 3 months, and even 222% in just 8 days. While the past is no sure indicator for the future… Those gains could pale in comparison to what's coming.March 10, 2025 | InvestorPlace (Ad)Insulet (NASDAQ:PODD) Coverage Initiated at Royal Bank of CanadaMarch 8 at 3:39 AM | americanbankingnews.comShort Interest in Insulet Co. (NASDAQ:PODD) Declines By 11.5%March 8 at 2:21 AM | americanbankingnews.comInsulet Corp. stock underperforms Thursday when compared to competitorsMarch 7 at 6:22 PM | marketwatch.comRBC Capital Initiates Coverage of Insulet (PODD) with Outperform RecommendationMarch 7 at 6:22 PM | msn.comInsulet Corp (PODD) Trading Down 4.02% on Mar 7March 7 at 5:05 PM | gurufocus.comSee More Headlines PODD Stock Analysis - Frequently Asked Questions How have PODD shares performed this year? Insulet's stock was trading at $261.07 at the beginning of the year. Since then, PODD stock has decreased by 9.2% and is now trading at $237.06. View the best growth stocks for 2025 here. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) announced its quarterly earnings results on Thursday, February, 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. The medical instruments supplier earned $597.50 million during the quarter, compared to analysts' expectations of $582.02 million. Insulet had a net margin of 20.19% and a trailing twelve-month return on equity of 24.46%. Who are Insulet's major shareholders? Top institutional investors of Insulet include Vanguard Group Inc. (12.10%), Capital Research Global Investors (10.62%), Baillie Gifford & Co. (3.36%) and Geode Capital Management LLC (2.54%). Insiders that own company stock include Charles Alpuche, Timothy J Scannell, James Hollingshead, Wayde D Mcmillan, Bret Christensen, Mark N Field, Eric Benjamin, Michael P Spears, Lauren Budden, Dan Manea, Prem Singh, Shacey Petrovic and Luciana Borio. View institutional ownership trends. How do I buy shares of Insulet? Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some other companies that Insulet investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Ford Motor (F), Bank of America (BAC), Wayfair (W) and Wells Fargo & Company (WFC). Company Calendar Last Earnings2/20/2025Today3/10/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:PODD CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees3,000Year Founded2000Price Target and Rating Average Stock Price Target$292.06 High Stock Price Target$355.00 Low Stock Price Target$200.00 Potential Upside/Downside+23.1%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)$5.79 Trailing P/E Ratio40.98 Forward P/E Ratio60.53 P/E Growth3.62Net Income$206.30 million Net Margins20.19% Pretax Margin14.95% Return on Equity24.46% Return on Assets8.33% Debt Debt-to-Equity Ratio1.21 Current Ratio3.68 Quick Ratio2.80 Sales & Book Value Annual Sales$2.07 billion Price / Sales8.04 Cash Flow$3.12 per share Price / Cash Flow75.96 Book Value$10.49 per share Price / Book22.62Miscellaneous Outstanding Shares70,226,000Free Float69,815,000Market Cap$16.66 billion OptionableOptionable Beta1.29 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:PODD) was last updated on 3/10/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrumps Tariffs Are Fueling This (collect your share)Trump's new tariffs are shaking up the economy—raising prices, disrupting industries, and forcing businesses t...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.